Roche Holding PT receives Investment Bank Analyst Rating Update
Many growth stocks and exchange-traded funds (ETFs) are currently changing hands around 52-week or even multi-year lows and the impending earnings season could bring more...
When we’re faced with a situation like today’s, with inflation and interest rates on a tear, we want dividends that keep us ahead of rising prices while hedging us...
Executive Summary Shareholder meetings and conferences ramp up after a busy summer and ahead of the next earnings season The Delta variant forced many companies to quickly switch...
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
|Average||376.070 (+14.48% Upside)|
|No. of Analysts||24|